Showing results (111-120 of 176) with videos related to
Sort By:
Pageof 18
BMC Cancer|February 26, 2016
Distribution and prognosis of uncommon metastases from non-small cell lung cancerFei-Yu Niu, Qing Zhou, Jin-Ji Yang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 12, 2017
Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic StrategiesZhong-Yi Dong, Chao Zhang, Yu-Fa Li, et al.Thoracic Cancer|April 19, 2022
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancerKai-Cheng Peng, Jun-Wei Su, Zhi Xie, et al.The New England Journal of Medicine|August 21, 2009
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaTony S Mok, Yi-Long Wu, Sumitra Thongprasert, et al.JTO Clinical and Research Reports|September 16, 2024
Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung AdenocarcinomaJia-Xin Lin, Kai Yin, Li-Xu Yan, et al.Translational Lung Cancer Research|September 29, 2021
The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment optionsJiu-Wei Cui, Qing Zhou, Shun Lu, et al.Journal of Translational Medicine|July 10, 2026
The effects of probiotics duration and type on immunotherapy efficacy in non-small cell lung cancer with or without antibioticsWei-Chi Luo, Zi-Jian Huang, Shi-Qi Mei, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2018
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR MutationShan Su, Zhong-Yi Dong, Zhi Xie, et al.Lung Cancer (Amsterdam, Netherlands)|October 20, 2012
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancerJin-Ji Yang, Hua-Jun Chen, Hong-Hong Yan, et al.Clinical Lung Cancer|June 6, 2022
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)Si-Yang Maggie Liu, Hong-Hong Yan, Xue-Wu Wei, et al.Pageof 18